Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263

Article  PubMed  Google Scholar 

Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147(2):275–292

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cao H, Zhang Z, Zhao S, He X, Yu H, Yin Q, Zhang Z, Gu W, Chen L, Li Y (2015) Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression. Journal of controlled release : official journal of the Controlled Release Society 205:162–171

Article  PubMed  CAS  Google Scholar 

Sundquist M, Brudin L, Tejler G (2017) Improved survival in metastatic breast cancer 1985–2016. Breast (Edinburgh, Scotland) 31:46–50

Article  PubMed  Google Scholar 

Hsu JY, Chang CJ, Cheng JS (2022) Survival, treatment regimens and medical costs of women newly diagnosed with metastatic triple-negative breast cancer. Sci Rep 12(1):729

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM et al (2015) Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst 107(6):djv048

Article  PubMed  PubMed Central  Google Scholar 

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106(5):dju055

Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F et al: A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. European journal of cancer (Oxford, England : 1990) 2014, 50(2):277–289.

Article  CAS  Google Scholar 

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J (2012) Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30(21):2601–2608

Article  PubMed  Google Scholar 

Park IH, Im SA, Jung KH, Sohn JH, Park YH, Lee KS, Sim SH, Park KH, Kim JH, Nam BH et al (2019) Randomized open label phase III trial of irinotecan plus capecitabine versus capecitabine monotherapy in patients with metastatic breast cancer previously treated with anthracycline and taxane: PROCEED trial (KCSG BR 11–01). Cancer Res Treat 51(1):43–52

Article  PubMed  CAS  Google Scholar 

Perez EA, Patel T, Moreno-Aspitia A (2010) Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 121(2):261–271

Article  PubMed  CAS  Google Scholar 

Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A (2016) Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy. Ann Oncol 27(8):1525–1531

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li CH, Karantza V, Aktan G, Lala M (2019) Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review. Breast Cancer Res BCR 21(1):143

Article  PubMed  Google Scholar 

Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang CH, Goldenberg DM (2015) Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res 21(22):5131–5138

Article  PubMed  CAS  Google Scholar 

Goldenberg DM, Stein R, Sharkey RM (2018) The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget 9(48):28989–29006

Article  PubMed  PubMed Central  Google Scholar 

Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, Simeone P, La Sorda R, Lattanzio R, Querzoli P, Pedriali M et al (2014) Trop-2 is a determinant of breast cancer survival. PLoS ONE 9(5):e96993

Article  PubMed  PubMed Central  Google Scholar 

Vidula N, Yau C, Rugo H (2022) Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer. Breast Cancer Res Treat 194(3):569–575

Article  PubMed  CAS  Google Scholar 

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O’Shaughnessy J, Moroose RL, Santin AD, Abramson VG et al (2019) Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380(8):741–751

Article  PubMed  CAS  Google Scholar 

Matusz-Fisher A, Tan AR (2022) Sacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer. Ann Transl Med 10(18):1031

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lopez S, Perrone E, Bellone S, Bonazzoli E, Zeybek B, Han C, Tymon-Rosario J, Altwerger G, Menderes G, Bianchi A et al (2020) Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. Oncotarget 11(5):560–570

Article  PubMed  PubMed Central  Google Scholar 

Goldenberg DM, Sharkey RM (2020) Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy. Expert Opin Biol Ther 20(8):871–885

Article  PubMed  CAS  Google Scholar 

Govindan SV, Cardillo TM, Sharkey RM, Tat F, Gold DV, Goldenberg DM (2013) Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol Cancer Ther 12(6):968–978

Article  PubMed  CAS  Google Scholar 

Kopp A, Hofsess S, Cardillo TM, Govindan SV, Donnell J, Thurber GM (2023) Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol Cancer Ther 22(1):102–111

Article  PubMed  CAS  Google Scholar 

Shvartsur A, Bonavida B (2015) Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 6(3–4):84–105

PubMed  PubMed Central  CAS  Google Scholar 

Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P et al (2023) Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet (London, England) 402(10411):1423–1433

Article  PubMed  CAS  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384(16):1529–1541

Article  PubMed  CAS  Google Scholar 

O’Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R et al (2022) Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat 195(2):127–139

Article  PubMed  PubMed Central  Google Scholar 

Xu B, Wang S, Yan M, Sohn J, Li W, Tang J, Wang X, Wang Y, Im SA, Jiang D et al (2024) Sacituzumab govitecan in HR(+)HER2(-) metastatic breast cancer: the randomized phase 3 EVER-132-002 trial. Nat Med 30(12):3709–3716

Article  PubMed  PubMed Central  CAS  Google Scholar 

Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet (London, England) 389(10087):2415–2429

Article  PubMed  CAS  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England) 376(9742):687–697

Article  PubMed